Stockreport

Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva Pharmaceutical Industries Limited American Depositary Shares  (TEVA) 
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm Check Earnings Report
US:NYSE Investor Relations: ir.tevapharm.com
PDF Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone condition [Read more]